Repair of diverse diabetic defects of β-cells in man and mouse by pharmacological glucokinase activation

Diabetes, Obesity and Metabolism

Volumn 14, Issue SUPPL.3, 2012, Pages 109-119

  Doliba, Nicolai M ^a   Fenner, Deborah ^b   Zelent, Bogumil ^a   Bass, Joseph ^b   Sarabu, Ramakanth ^c   Matschinsky, Franz M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

Diabetes therapy; Glucokinase; Glucokinase activators; cells

Indexed keywords

ETHYLNITROSOUREA; GLIBENCLAMIDE; GLUCOKINASE; PIRAGLIATIN; SULFONYLUREA;

BIOENERGY; CALCIUM METABOLISM; CELL FUNCTION; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME POLYMORPHISM; HUMAN; INSULIN RELEASE; NONHUMAN; ORGAN CULTURE; PANCREAS ISLET BETA CELL; REVIEW; TISSUE CULTURE;

EID: 84865574804     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01652.x     Document Type: Review

References (63)

1. Matschinsky FM, Magnuson MA, Zelent D et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 2006; 55: 1-12.
2. Matschinsky FM, Porte D. Glucokinase activators (GKAs) promise a new pharmacotherapy for diabetics. F1000 Med Rep 2010; 2: 43.
3. Cuesta-Munoz AL, Huopio H, Otonkoski T et al. Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes 2004; 53: 2164-2168.
4. Njolstad PR, Sovik O, Cuesta-Munoz A, Bjorkhaug L et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 2001; 344: 1588-1592.
5. Njolstad PR, Sagen JV, Bjorkhaug L et al. Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway. Diabetes 2003; 52: 2854-60.
6. Glaser B, Kesavan P, Heyman M, Davis E et al. Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 1998; 338: 226-230.
7. Christesen HB, Jacobsen BB, Odili S et al. The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes 2002; 51: 1240-1246.
8. Gloyn AL, Noordam K, Willemsen MA et al. Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes 2003; 52: 2433-2440.
9. Cuesta-Munoz AL, Tuomi T, Cobo-Vuilleumier N et al. Clinical heterogeneity in monogenic diabetes caused by mutations in the glucokinase gene (GCK-MODY). Diabetes Care 2010; 33: 290-292.
10. Froguel P, Vaxillaire M, Sun F et al. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature 1992; 356: 162-164.
11. Hattersley AT, Turner RC, Permutt MA et al. Linkage of type 2 diabetes to the glucokinase gene. Lancet 1992; 339: 1307-1310.
12. Grimsby J, Sarabu R, Corbett WL et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003; 301: 370-373.
13. Bonadonna RC, Kapitza C, Heise T et al. Glucokinase activator R04389620 improves beta cell function and plasma glucose fluxes in patients with type 2 diabetes. Diabetologia 2008; 51(Suppl. 1): S371.
14. Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009; 8: 399-416.
15. Zhi J, Zhai S, Mulligan ME, Grimsby J et al. A novel glucokinase activator RO4389620 improved fasting and postprandial plasma glucose in type 2 diabetic patients. Diabetologia 2008; 51(Suppl. 1): S23.
16. Meininger GE, Scott R, Alba M et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 2011; 34: 2560-2566.
17. Matschinsky FM. Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 1996; 45: 223-241.
18. Matschinsky FM. Glucokinase, glucose homeostasis, and diabetes mellitus. Curr Diab Rep 2005; 5: 171-176.
19. Cardenas ML, Cornish-Bowden A, Ureta T. Evolution and regulatory role of the hexokinases. Biochim Biophys Acta 1998; 1401: 242-264.
20. Zelent D, Najafi H, Odili S et al. Glucokinase and glucose homeostasis: proven concepts and new ideas. Biochem Soc Trans 2005; 33: 306-310.
21. Lin SX, Neet KE. Demonstration of a slow conformational change in liver glucokinase by fluorescence spectroscopy. J Biol Chem 1990; 265: 9670-9675.
22. Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 2004; 12: 429-438.
23. Zelent B, Buettger C, Grimsby J et al. Thermal stabilty of glucokinase (GK) as influenced by the substrate glucose, an allosteric glucokinase activator drug (GKA) and the osmolytes glycerol and urea. Biochim Biophys Acta 2012; 1824: 769-784.
24. Matschinsky FM, Zelent B, Doliba NM et al. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects. Handb Exp Pharmacol 2011; 203: 357-401.
25. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 2000; 49: 1751-1760.
26. Kawamori D, Welters HJ, Kulkarni RN. Molecular pathways underlying the pathogenesis of pancreatic alpha-cell dysfunction. Adv Exp Med Biol 2010; 654: 421-445.
27. Ishihara H, Maechler P, Gjinovci A, Herrera PL, Wollheim CB. Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. Nat Cell Biol 2003; 5: 330-335.
28. Walker JN, Ramracheya R, Zhang Q, Johnson PR, Braun M, Rorsman P. Regulation of glucagon secretion by glucose: paracrine, intrinsic or both? Diabetes Obes Metab 2011; 13(Suppl. 1): 95-105.
29. Matschinsky FM, Pagliara AS, Hover BA, Pace CS, Ferrendelli JA, Williams A. Hormone secretion and glucose metabolism in islets of Langerhans of the isolated perfused pancreas from normal and streptozotocin diabetic rats. J Biol Chem 1976; 251: 6053-6061.
30. Bedoya FJ, Oberholtzer JC, Matschinsky FM. Glucokinase in B-cell-depleted islets of Langerhans. J Histochem Cytochem 1987; 35: 1089-1093.
31. Fenner D, Odili S, Hong HK et al. Generation of N-ethyl-N-nitrosourea (ENU) diabetes models in mice demonstrates genotype-specific action of glucokinase activators. J Biol Chem 2011; 286: 39560-39572.
32. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
33. Riedel AA, Heien H, Wogen J, Plauschinat CA. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 2007; 27: 1102-1110.
34. Ohyama S, Takano H, Iino T et al. A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat. Eur J Pharmacol 2010; 640: 250-256.
35. Li C, Buettger C, Kwagh J, Matter A et al. A signaling role of glutamine in insulin secretion. J Biol Chem 2004; 279: 13393-13401.
36. Sivitz WI. Lipotoxicity and glucotoxicity in type 2 diabetes. Effects on development and progression. Postgrad Med 2001; 109(55-9): 63-4.
37. Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 2009; 26: 1185-1192.
38. Doliba NM, Qin W, Vatamaniuk MZ et al. Restitution of defective glucose-stimulated insulin release of sulfonylurea type 1 receptor knockout mice by acetylcholine. Am J Physiol Endocrinol Metab 2004; 286: E834-E843.
39. Wellendorph P, Johansen LD, Brauner-Osborne H. Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients. Mol Pharmacol 2009; 76: 453-465.
40. De Leon DD, Li C, Delson MI, Matschinsky FM, Stanley CA, Stoffers DA. Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion. J Biol Chem 2008; 283: 25786-25793.
41. De Leon D, Stanley CA. Pathophysiology of diffuse ATP-sensitive potassium channel hyperinsulinism. In: Stanley C, De Leon DD, eds. Monogenic Hyperinsulinemic Hypoglycemia Disorders. Front Diabetes. Basel: Karger, 2012; 18-29.
42. Kyriazis GA, Soundarapandian MM, Tyrberg B. Sweet taste receptor signaling in beta cells mediates fructose-induced potentiation of glucose-stimulated insulin secretion. Proc Natl Acad Sci USA 2012; 109: E524-E532.
43. Kojima I, Nakagawa Y. The role of the sweet taste receptor in enteroendocrine cells and pancreatic beta-cells. Diabetes Metab J 2011; 35: 451-457.
44. Doliba NM, Qin W, Najafi H et al. Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics. Am J Physiol Endocrinol Metab 2012; 302: E87-E102.
45. Ehses JA, Boni-Schnetzler M, Faulenbach M, Donath MY. Macrophages, cytokines and beta-cell death in Type 2 diabetes. Biochem Soc Trans 2008; 36: 340-342.
46. Matschinsky FM, Ellerman JE. Metabolism of glucose in the islets of Langerhans. J Biol Chem 1968; 243: 2730-2736.
47. Bedoya FJ, Wilson JM, Ghosh AK, Finegold D, Matschinsky FM. The glucokinase glucose sensor in human pancreatic islet tissue. Diabetes 1986; 35: 61-67.
48. Leech CA, Dzhura I, Chepurny OG et al. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic beta cells. Prog Biophys Mol Biol 2011; 107: 236-247.
49. Iynedjian PB. Mammalian glucokinase and its gene. Biochem J 1993; 293: 1-13.
50. Heimberg H, De Vos A, Moens K et al. The glucose sensor protein glucokinase is expressed in glucagon-producing alpha-cells. Proc Natl Acad Sci USA 1996; 93: 7036-7041.
51. Leibiger IB, Walther R, Pett U, Leibiger B. Positive and negative regulatory elements are involved in transcriptional control of the rat glucokinase gene in the insulin producing cell line HIT M2.2.2. FEBS Lett 1994; 337: 161-166.
52. Payne VA, Arden C, Lange AJ, Agius L. Contributions of glucokinase and phosphofructokinase-2/fructose bisphosphatase-2 to the elevated glycolysis in hepatocytes from Zucker fa/fa rats. Am J Physiol Regul Integr Comp Physiol 2007; 293: R618-R625.
53. Danial NN, Walensky LD, Zhang CY et al. Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat Med 2008; 14: 144-153.
54. Danial NN, Gramm CF, Scorrano L et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 2003; 424: 952-956.
55. Miwa I, Toyoda Y, Yoshie S. Glucokinase in beta-cell insulin secretory granules. In: Matschinsky F, Magnuson MA, eds. Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Basel: Karger, 2004; 350-359.
56. Vandercammen A, Van Schaftingen E. The mechanism by which rat liver glucokinase is inhibited by the regulatory protein. Eur J Biochem 1990; 191: 483-489.
57. Shamas-Din A, Brahmbhatt H, Leber B, Andrews DW. BH3-only proteins: Orchestrators of apoptosis. Biochim Biophys Acta 2011; 1813: 508-520.
58. Arden C, Baltrusch S, Agius L. Glucokinase regulatory protein is associated with mitochondria in hepatocytes. FEBS Lett 2006; 580: 2065-2070.
59. Danial NN. BAD: undertaker by night, candyman by day. Oncogene 2008; 27(Suppl. 1): S53-S70.
60. Osundiji MA, Godes ML, Evans ML, Danial NN. BAD modulates counterregulatory responses to hypoglycemia and protective glucoprivic feeding. PLoS One 2011; 6: e28016.
61. Terauchi Y, Takamoto I, Kubota N et al. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 2007; 117: 246-257.
62. Rudic RD, McNamara P, Reilly D et al. Bioinformatic analysis of circadian gene oscillation in mouse aorta. Circulation 2005; 112: 2716-2724.
63. Doliba NM, Qin W, Vatamaniuk MZ et al. Cholinergic regulation of fuel-induced hormone secretion and respiration of SUR1-/- mouse islets. Am J Physiol Endocrinol Metab 2006; 291: E525-E535.